Loading...

POSTERS

AI assisted whole body assessment of immunotherapy response using [ 18 F]F AraG , a PET agent for activated T cells

Analysis and quantification of 18 F]F AraG PET using TRAQinform IQ technology provides patient level assessment of all areas with tracer uptake and may allow for better understanding of heterogeneity of T cell activation and potentially offer a more comprehensive evaluation of response to immunotherapy than the standard, tumor centric, radiologic methods.

Automated Segmentation and Quantitation of PET/CT Images Using 124I-p5+14 (AT-01) in Patients with AL and ATTR Amyloidosis

Given the novelty of the AT-01 radiotracer and the heterogeneous presentation of disease in this patient population, this automated approach to image analysis of AT-01 PET/CT data would be an invaluable tool for novice readers and those seeking to quantify amyloid burden longitudinally without introducing reader bias. This approach will significantly impact the ease of use and improve accuracy of image interpretation that will ultimately benefit clinical management of patients with amyloidosis.

Spatial-Temporal Change in Quantitative Total Bone Imaging and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide

Cancer is a dynamic disease which, over time, may result in nonuniform distribution of distinct tumor cell subpopulations at different sites (spatial heterogeneity) or an increase in molecularly diverse cells (temporal heterogeneity). Here we report the exploratory objectives of tumor burden and CTC analysis using QTBI and VERSA in men with mCRPC to bone treated with enzalutamide.

Interlesional Response Assessment With 18F-Sodium Fluoride (18F-NaF) PET/CT in Men With Chemotherapy-Naive Bone Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide

18F-NaF positron emission tomography/computed tomography (PET/CT) scan is an approved tool to detect and evaluate osteoblastic metastases that is more sensitive and specific than conventional bone scintigraphy. Here we assess the proportion of men treated with enzalutamide with responding lesions by 18F-NaF PET/CT scan at the time of prostate-specific antigen (PSA), standard radiographic, or clinical progression.

Spatiotemporal evolution of lesion response heterogeneity to 177Lu-DOTATATE therapy in advanced gastroenteropancreatic neuroendocrine tumors

The purpose of this investigation was to understand and quantify the inter-lesion heterogeneity in treatment response seen on 68Ga-DOTATATE PET/CT imaging over the course of Lutathera therapy

AIQ's software has been cleared for clinical use under 510(k) K173444. For details, including the applicable Indications for Use,
see: https://www.accessdata.fda.gov/scripts/cdrh/cfcodes/cfPMN/pmn.cfm?ID=K173444